InMed Pharmaceuticals: Leading the Way in Rare Cannabinoids

January 10, 2020

Rare cannabinoids have potential to treat skin and eye diseases

InMed Pharmaceuticals is a leader in developing rare cannabinoids and their potential to treat serious skin and eye diseases. They are a clinical-stage biopharmaceutical company developing a proprietary biosynthesis platform for the manufacturing of pharmaceutical-grade cannabinoids. In addition, they're developing a pipeline of cannabinoid-based medications that target diseases with high unmet medical needs. Moreover, InMed focuses in delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.  

Cannabinoid Science

The majority of pharmaceutical and academic research & development activities investigating the physiological and disease-fighting properties of cannabis revolves around the understanding of one class of biologically active ingredients, the cannabinoids. In the 1960s, several interesting compounds were isolated from the cannabis plant. There are over 100 different cannabinoids. However, the two most well-known and studied compounds in the cannabis plant also happen to be the two that occur in the largest quantity: Δ9-tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”).

About Biosynthesis

Biosynthesis is the process of genetically modifying an organism to produce a pharmaceutically bioactive compound; that it otherwise would not normally make. Manufacturing of pharmaceutical-grade cannabinoids remains a challenge. Especially for those that are in only trace amounts in the cannabis plant but may hold important physiological benefits in humans. Further, InMed recognizes that having a reliable source of pure, pharmaceutical-grade starting materials for its products that are bio-identical to the compounds that you can find in nature is a critical success factor for its drug development strategy.

For more information on InMed Pharmaceuticals Inc. (IN:TSX, IMLFF:OTCQX) please fill out the form below.

You might also like

Cannabis
CSE - Verano: U.S Based Multi-State Cannabis Operator

Verano designs, builds, and operates dispensaries under retail brands including Zen Leaf™ and MÜV™, delivering a superior cannabis shopping experience in both medical and adult-use markets.

Cannabis
CEO Clips - Schwazze: From Seed to Sale

Schwazze is focused on building the premier vertically integrated cannabis company in Colorado. They are the parent company of a portfolio of cannabis …

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, YouTube and more!